Clinical Trial Update: Safety and Efficacy of IGIV 10% in Patients With Autoimmune Encephalitis: [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety and efficacy of IGIV 10% in autoimmune encephalitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autoimmune Encephalitis

Drugs mentioned

• IGIV 10%

Snippet

Sponsor: Green Cross Corporation | Conditions: Autoimmune Encephalitis | Phase 2 | Status: COMPLETED